Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTX NASDAQ:IKT NASDAQ:INCR NASDAQ:LENZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTXContext Therapeutics$1.39-2.1%$2.34$0.56▼$3.62$130.47M1.61706,714 shs498,614 shsIKTInhibikase Therapeutics$1.67$1.77$1.33▼$2.26$220.49M0.92660,740 shs423,859 shsINCRInterCure$0.87+0.3%$0.86$0.68▼$1.77$47.63M1.3834,845 shs494,487 shsLENZLENZ Therapeutics$6.77+4.2%$8.48$6.28▼$50.40$203.80M0.58667,225 shs283,633 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTXContext Therapeutics-2.07%-30.05%-42.74%-57.74%+128.92%IKTInhibikase Therapeutics+0.60%+0.30%-13.02%-16.50%+166,999,900.00%INCRInterCure+2.46%-17.05%+7.53%+10.25%-43.26%LENZLENZ Therapeutics-1.22%-9.72%-17.83%-46.50%-78.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTXContext Therapeutics$1.39-2.1%$2.34$0.56▼$3.62$130.47M1.61706,714 shs498,614 shsIKTInhibikase Therapeutics$1.67$1.77$1.33▼$2.26$220.49M0.92660,740 shs423,859 shsINCRInterCure$0.87+0.3%$0.86$0.68▼$1.77$47.63M1.3834,845 shs494,487 shsLENZLENZ Therapeutics$6.77+4.2%$8.48$6.28▼$50.40$203.80M0.58667,225 shs283,633 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTXContext Therapeutics-2.07%-30.05%-42.74%-57.74%+128.92%IKTInhibikase Therapeutics+0.60%+0.30%-13.02%-16.50%+166,999,900.00%INCRInterCure+2.46%-17.05%+7.53%+10.25%-43.26%LENZLENZ Therapeutics-1.22%-9.72%-17.83%-46.50%-78.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTXContext Therapeutics 2.88Moderate Buy$6.60374.82% UpsideIKTInhibikase Therapeutics 3.11Buy$5.40223.35% UpsideINCRInterCure 1.00SellN/AN/ALENZLENZ Therapeutics 2.50Moderate Buy$29.80340.18% UpsideCurrent Analyst Ratings BreakdownLatest INCR, IKT, LENZ, and CNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026IKTInhibikase Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.005/13/2026LENZLENZ Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$26.00 ➝ $20.005/12/2026LENZLENZ Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$39.00 ➝ $12.005/12/2026LENZLENZ Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$48.00 ➝ $38.004/21/2026IKTInhibikase Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026LENZLENZ Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026LENZLENZ Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$56.00 ➝ $48.004/20/2026CNTXContext Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026INCRInterCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/26/2026LENZLENZ Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$52.00 ➝ $26.003/25/2026LENZLENZ Therapeutics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$35.00 ➝ $29.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTXContext TherapeuticsN/AN/AN/AN/A$0.66 per shareN/AIKTInhibikase Therapeutics$260K848.04N/AN/A$2.30 per share0.73INCRInterCure$78.47M0.61N/AN/A$2.11 per share0.41LENZLENZ Therapeutics$19.09M11.12N/AN/A$9.09 per share0.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTXContext Therapeutics-$36.12M-$0.42N/AN/AN/AN/A-59.95%-54.78%8/5/2026 (Estimated)IKTInhibikase Therapeutics-$48.26M-$0.43N/AN/AN/AN/A-41.31%-38.98%N/AINCRInterCure-$10.37M$0.03N/AN/AN/AN/AN/AN/AN/ALENZLENZ Therapeutics-$82.13M-$3.60N/AN/AN/A-519.30%-46.82%-43.32%7/29/2026 (Estimated)Latest INCR, IKT, LENZ, and CNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026IKTInhibikase Therapeutics-$0.10-$0.10N/A-$0.10N/AN/A5/11/2026Q1 2026LENZLENZ Therapeutics-$1.10-$1.32-$0.22-$1.32$1.76 million$1.90 million5/6/2026Q1 2026CNTXContext Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/A4/30/2026Q4 2025INCRInterCureN/A-$0.10N/A-$0.10N/A$23.15 million3/26/2026Q4 2025IKTInhibikase Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/A3/24/2026Q4 2025LENZLENZ Therapeutics-$0.91-$1.16-$0.25-$1.16$3.09 million$1.59 million3/23/2026Q4 2025CNTXContext Therapeutics-$0.11-$0.14-$0.03-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNTXContext TherapeuticsN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTXContext TherapeuticsN/A8.968.96IKTInhibikase TherapeuticsN/A30.1430.14INCRInterCure0.201.480.97LENZLENZ TherapeuticsN/A10.4010.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTXContext Therapeutics14.03%IKTInhibikase Therapeutics3.81%INCRInterCure8.34%LENZLENZ Therapeutics54.32%Insider OwnershipCompanyInsider OwnershipCNTXContext Therapeutics4.80%IKTInhibikase Therapeutics7.30%INCRInterCure0.24%LENZLENZ Therapeutics8.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTXContext Therapeutics791.88 million87.47 millionNot OptionableIKTInhibikase Therapeutics6132.03 million122.40 millionN/AINCRInterCure35054.68 million54.55 millionOptionableLENZLENZ Therapeutics11031.35 million28.75 millionN/AINCR, IKT, LENZ, and CNTX HeadlinesRecent News About These CompaniesLENZ Therapeutics adds China partner for presbyopia drug VIZZJune 8, 2026 | proactiveinvestors.comLENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize ...June 8, 2026 | caledonianrecord.comCLENZ Therapeutics, Inc.: LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ (LNZ100) in Greater ChinaJune 8, 2026 | finanznachrichten.deEverest Medicines acquires Greater China rights for LENZ Therapeutics' presbyopia eyedrop VIZZ®June 8, 2026 | seekingalpha.comLENZ Therapeutics and Everest Medicines Form Strategic Partnership for Development and Commercialization of VIZZ in Greater ChinaJune 7, 2026 | quiverquant.comQLENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater ChinaJune 7, 2026 | globenewswire.comLENZ Therapeutics to Participate in Upcoming Investor ConferencesMay 26, 2026 | globenewswire.comFDA approves VIZZ eye drops as alternative to reading glassesMay 26, 2026 | msn.comLENZ Therapeutics Inc.May 23, 2026 | marketwatch.comThings Look Grim For LENZ Therapeutics, Inc. (NASDAQ:LENZ) After Today's DowngradeMay 16, 2026 | finance.yahoo.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Have Been Cutting Their EstimatesMay 14, 2026 | finance.yahoo.comLENZ Therapeutics Inc (LENZ) Q1 2026 Earnings Call Highlights: Strong Prescription Growth Amid ...May 12, 2026 | finance.yahoo.comLENZ Therapeutics reports Q1 growth as VIZZ adoption buildsMay 11, 2026 | msn.comLENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsMay 11, 2026 | finance.yahoo.comLENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call TranscriptMay 11, 2026 | seekingalpha.comLENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue EstimatesMay 11, 2026 | zacks.comLENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor ConferenceMay 4, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), Maravai Lifesciences Holdings (MRVI) and LENZ Therapeutics (LENZ)April 22, 2026 | theglobeandmail.comLENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of ...April 20, 2026 | markets.businessinsider.comLENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United KingdomApril 20, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesQualcomm's TikTok AI Chip Deal Rewrites the RulesBy Jeffrey Neal Johnson | May 27, 2026From High-Yield to High-Growth: 3 Stocks Boosting DividendsBy Leo Miller | May 18, 20263 Crucial Aerospace Component Makers That Analysts LoveBy Nathan Reiff | May 16, 20263 Dividend Kings That Earn Their Crown Every QuarterBy Chris Markoch | May 31, 2026Record Revenue, Rising Dividends—So Why Aren't Analysts Saying Buy?By Peter Frank | May 27, 2026INCR, IKT, LENZ, and CNTX Company DescriptionsContext Therapeutics NASDAQ:CNTX$1.39 -0.03 (-2.11%) Closing price 04:00 PM EasternExtended Trading$1.34 -0.05 (-3.38%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Inhibikase Therapeutics NASDAQ:IKT$1.67 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.68 +0.01 (+0.66%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.InterCure NASDAQ:INCR$0.87 +0.00 (+0.34%) Closing price 04:00 PM EasternExtended Trading$0.87 0.00 (-0.23%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.LENZ Therapeutics NASDAQ:LENZ$6.77 +0.27 (+4.15%) Closing price 04:00 PM EasternExtended Trading$6.74 -0.03 (-0.50%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
